MedTrace Logo

Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer

NCT00479856 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2012-06-05

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety and efficacy of lapatinib in combination with chemotherapy (capecitabine, docetaxel, nab-paclitaxel) in subjects with ErbB2-overexpressing breast cancer whose disease has progressed during or within 12 months after completion of trastuzumab-containing therapy in the neoadjuvant or adjuvant setting.

Conditions

  • Relapsed Breast Cancer
  • Neoplasms, Breast

Interventions

DRUG

Lapatinib

Small molecule tyrosine kinase inhibitor

DRUG

Capecitabine

Chemotherapy

DRUG

Docetaxel

Chemotherapy

DRUG

nab-Paclitaxel

Chemotherapy

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2009-09-30
Completion
2010-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00479856 on ClinicalTrials.gov